Penna A - Search Results

1

Primary gastro-duodenal acute myeloid leukemia presenting as persisting vomiting.

Tursi A, Penna A, Lozupone A. Tursi A, et al. Among authors: penna a. Dig Liver Dis. 2017 May;49(5):576-577. doi: 10.1016/j.dld.2017.03.007. Epub 2017 Mar 21. Dig Liver Dis. 2017. PMID: 28385390 No abstract available.

2

Onset of ulcerative colitis under treatment with adalimumab.

Tursi A, Penna A. Tursi A, et al. Among authors: penna a. Am J Gastroenterol. 2008 Sep;103(9):2410-2. doi: 10.1111/j.1572-0241.2008.02010_11.x. Am J Gastroenterol. 2008. PMID: 18844636 No abstract available.

3

Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.

Tursi A, Elisei W, Brandimarte G, Giorgetti G, Penna A, Castrignano V. Tursi A, et al. Among authors: penna a. Eur Rev Med Pharmacol Sci. 2010 Jan;14(1):47-55. Eur Rev Med Pharmacol Sci. 2010. PMID: 20184089 Clinical Trial.

4

Crohn's appendicitis.

Tursi A, Penna A. Tursi A, et al. Among authors: penna a. Endoscopy. 2010;42 Suppl 2:E84. doi: 10.1055/s-0029-1243872. Epub 2010 Mar 1. Endoscopy. 2010. PMID: 20195978 No abstract available.

5

Effectiveness of different therapeutic strategies in preventing diverticulitis recurrence.

Tursi A, Elisei W, Giorgetti GM, Inchingolo CD, Nenna R, Picchio M, Maiorano M, Penna A, Lecca PG, Brandimarte G. Tursi A, et al. Among authors: penna a. Eur Rev Med Pharmacol Sci. 2013 Feb;17(3):342-8. Eur Rev Med Pharmacol Sci. 2013. PMID: 23426537 Free article.

6

Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?

Tursi A, Elisei W, Picchio M, Penna A. Tursi A, et al. Among authors: penna a. Aliment Pharmacol Ther. 2013 Apr;37(7):763-4. doi: 10.1111/apt.12238. Aliment Pharmacol Ther. 2013. PMID: 23458543 No abstract available.

7

factors influencing mucosal healing in Crohn's disease during infliximab treatment.

Tursi A, Elisei W, Giorgetti GM, Penna A, Picchio M, Brandimarte G. Tursi A, et al. Among authors: penna a. Hepatogastroenterology. 2013 Jul-Aug;60(125):1041-6. doi: 10.5754/hge11514. Hepatogastroenterology. 2013. PMID: 23803367

8

Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.

Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G, Brandimarte G. Tursi A, et al. Among authors: penna a. Eur J Intern Med. 2014 Jun;25(5):485-90. doi: 10.1016/j.ejim.2014.02.010. Epub 2014 Mar 13. Eur J Intern Med. 2014. PMID: 24631020

9

Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers.

Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G, Brandimarte G. Tursi A, et al. Among authors: penna a. Eur J Intern Med. 2014 Oct;25(8):757-61. doi: 10.1016/j.ejim.2014.07.007. Epub 2014 Jul 30. Eur J Intern Med. 2014. PMID: 25086677

10

Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab.

Tursi A, Elisei W, Picchio M, Forti G, Penna A, Inchingolo CD, Nenna R, Brandimarte G. Tursi A, et al. Among authors: penna a. Clin Res Hepatol Gastroenterol. 2015 Feb;39(1):107-13. doi: 10.1016/j.clinre.2014.07.012. Epub 2014 Aug 28. Clin Res Hepatol Gastroenterol. 2015. PMID: 25176588

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

369 results

Search Page

Filters